Neuroendocrine Tumors – Epidemiology Forecast to 2030

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

The burden of diagnosed neuroendocrine tumors (NETs) is expected to increase at an annual growth rate (AGR) of 2.37% from an estimated 108,000 cases in 2020 to 133,000 in 2030 in the eight major markets (8MM*). This report reveals that the increase is attributed to the underlying demographic changes in the respective markets, and improvement in imaging tools used in diagnosis.

Slide1 (1).PNG

In the 8MM, China accounts for approximately 36% of all diagnosed incident cases due to its large population. In the five European markets (5EU), the UK accounts for the highest number of diagnosed incident cases of NETs with approximately 6,200 cases and 24% of all 5EU diagnosed incident cases of NETs.

Ana Fernandez Menjivar, MSc DLSHTM, Senior Epidemiologist at GlobalData, comments: “An increase in the diagnosed incidence of NETs has been reported worldwide. The reason for this rise is not completely understood, but is most likely due to increased physician awareness, improvements in diagnostic imaging tests used and increased use of these tools. Incidental diagnosis is also a factor as NETs may be diagnosed during routine screenings for an unrelated caused such a colonoscopy, MRI or endoscopy.

“An increase in incidental diagnosis could lead to more NET cases being diagnosed at earlier stages and identification of less aggressive indolent tumors that may not have been diagnosed otherwise.”

*8MM: The US, 5EU (France, Germany, Italy, Spain, the UK), Japan, and urban China.

Scope

NETs are cancers that begin in the cells that release hormones into the bloodstream. NETs can occur anywhere in the body. Most develop slowly and may not cause symptoms in the early stages. The symptoms associated with NETs vary depending on where in the body they originate. Gastrointestinal (GI) NETs may cause diarrhea, constipation, or stomach pains, and lung NETs may cause wheezing or a persistent cough. Other symptoms include flushing, cramps, low blood sugar, or heart problems. The exact cause of NETs is not known, but they develop when neuroendocrine cells develop mutations in the DNA.

To forecast the diagnosed incident cases of NETs, and five-year diagnosed prevalent cases of NETs in the 8MM, GlobalData epidemiologists conducted a thorough literature review to find country-specific sources that provided data for the above-mentioned segmentations of the general population in the 8MM. In order to improve the accuracy of the forecast GlobalData epidemiologists used studies that provided data based on uniform diagnostic codes and disease definition for these parameters across the 8MM.

In the 8MM, GlobalData epidemiologists forecast that the diagnosed incident cases of NETs will increase from 107,776 cases in 2020 to 133,312 cases in 2030, at an Annual Growth Rate (AGR) of 2.37%. Urban China will have the highest number of NET cases among the 8MM throughout the forecast period, while Spain will have the lowest. In the 8MM, GlobalData epidemiologists forecast that the five-year diagnosed prevalent cases of NETs will increase from 372,035 cases in 2020 to 465,410 cases in 2030, at an AGR of 2.51%.

  • The Neuroendocrine Tumors (NET) Epidemiology Report and Epidemiology Model provide an overview of the risk factors and global trends of NETs in the 8MM (US, France, Germany, Italy, Spain, UK, Japan, and urban China). It includes a 10-year epidemiological forecast for the diagnosed incident cases of NETs, based on country-specific studies published in peer-reviewed journals. The diagnosed incident cases of NETs are further segmented by sex, age, type, stage at diagnosis, grade and differentiation. GlobalData epidemiologists also provide diagnosed incident cases of paraganglioma and pheochromocytoma. The forecast also includes five-year diagnosed prevalent cases of NETs in the 8MM for the forecast period.
  • The neuroendocrine tumors epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.
  • The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to Buy

The Neuroendocrine Tumors Epidemiology Report and Model will allow you to:

Develop business strategies by understanding the trends shaping and driving the global hyperparathyroidism market.

Quantify patient populations in the global neuroendocrine tumors market to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the age groups, sex and type of NET that present the best opportunities for therapeutics in each of the markets covered.

Understand the population of paraganglioma and pheochromocytoma cases.

Table of Contents

Table of Contents

| About GlobalData

1 Neuroendocrine Tumors: Executive Summary

1.1 Related Reports

1.2 Upcoming Reports

2 Epidemiology

2.1 Disease Background

2.2 Risk Factors and Comorbidities

2.3 Global and Historical Trends

2.4 8MM Forecast Methodology

2.4.1 Sources

2.4.2 Forecast Assumptions and Methods: Population – 8MM

2.4.3 Forecast Assumptions and Methods: Diagnosed Incident Cases of NETs – 8MM

2.4.4 Forecast Assumptions and Methods: Diagnosed Incident Cases of NETs by Type

2.4.5 Forecast Assumptions and Methods: Diagnosed Incident Cases of NETs by Stage and Type

2.4.6 Forecast Assumptions and Methods: Diagnosed Incident Cases of NETs by Grade and Differentiation

2.4.7 Forecast Assumptions and Methods: Five-Year Diagnosed Prevalent Cases of NETs

2.5 Epidemiological Forecast for NETs, 2020-2030

2.5.1 Diagnosed Incident Cases of NETs

2.5.2 Age-Specific Diagnosed Incident Cases of NETs

2.5.3 Sex-Specific Diagnosed Incident Cases of NETs

2.5.4 Diagnosed Incident Cases of NETs by Type

2.5.5 Diagnosed Incident Cases of NETs by Type and Stage at Diagnosis

2.5.6 Diagnosed Incident Cases of NETs by Grade and Differentiation

2.5.7 Five-Year Diagnosed Prevalent Cases of NETs

2.6 Discussion

2.6.1 Epidemiological Forecast Insight

2.6.2 COVID-19 Impact

2.6.3 Limitations of the Analysis

2.6.4 Strengths of the Analysis

3 Appendix

3.1 Bibliography

3.2 About the Authors

3.2.1 Epidemiologist

3.2.2 Reviewers

3.2.3 Global Director of Therapy Analysis and Epidemiology

3.2.4 Global Head and EVP of Healthcare Operations and Strategy

| Contact Us

Table

Table 1: Risk Factors and Comorbidities for NETs

Figures

Figure 1: 8MM, Diagnosed Incident Cases of NETs, Both Sexes, N, All Ages, 2020 and 2030

Figure 2: 8MM, Diagnosed Incidence of NETs, Men, Cases per 100,000 Population, All Ages, 2010 and 2020

Figure 3: 8MM, Diagnosed Incidence of NETs, Women, Cases per 100,000 Population, All Ages, 2010 and 2020

Figure 4: 8MM, Sources Used and Not Used to Forecast the Diagnosed Incident Cases of NETs

Figure 5: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of NETs by Type

Figure 6: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of NETs by Stage at Diagnosis, by Type

Figure 7: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of NETs by Grade and Differentiation, by Type

Figure 8: 8MM, Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases of NETs

Figure 9: 8MM, Diagnosed Incident Cases of NETs, N, Both Sexes, All Ages, 2020

Figure 10: 8MM, Diagnosed Incident Cases of NETs by Age, N, Both Sexes, 2020

Figure 11: 8MM, Diagnosed Incident Cases of NETs by Sex, N, All Ages, 2020

Figure 12: 8MM, Diagnosed Incident Cases of NETs by Type, N, Both Sexes, 2020

Figure 13: 8MM, Diagnosed Incident Cases of NETs by Type and Stage at Diagnosis, N, Both Sexes, All Ages, 2020

Figure 14: 8MM, Diagnosed Incident Cases of NETs by Grade and Differentiation, N, Both Sexes, All Ages, 2020

Figure 15: 8MM, Five-Year Diagnosed Prevalent Cases of NETs, N, Both Sexes, All Ages, 2020

Frequently asked questions

Neuroendocrine Tumors – Epidemiology Forecast to 2030 standard reports
Currency USD
$3,995

Can be used by individual purchaser only

$11,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Neuroendocrine Tumors – Epidemiology Forecast to 2030 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS

Related reports

View more Oncology reports
Pharmaceuticals
New
Bio/Pharmaceutical Outsourcing Report, September 2026
$2,950 | October 2026
Pharmaceuticals
New
IDWeek 2026: Pre-Conference Coverage
$1,500 | October 2026
Pharmaceuticals
New
Gonorrhea: Market View, Current and Future Competitive Landscape
$3,495 | October 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Neuroendocrine Tumors – Epidemiology Forecast to 2030 in real time.

  • Access a live Neuroendocrine Tumors – Epidemiology Forecast to 2030 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.